Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 12/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.64 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096474 | 0.90 | HDAC11 (0.82) | HDAC11HDAC6DRD2DRD3KCNH2 | |
| SCHEMBL20096840 | 0.88 | HDAC11 (0.83) | HDAC11HDAC6HDAC1 | |
| SCHEMBL20096483 | 0.87 | HDAC11 (0.79) | HDAC11HDAC6HDAC1 | |
| SCHEMBL20096906 | 0.87 | HDAC11 (0.80) | HDAC11HDAC6P2RX7RIPK1 | |
| SCHEMBL20096737 | 0.86 | HDAC11 (0.78) | HDAC11HDAC6DRD3KCNH2HDAC1 | |
| SCHEMBL20096913 | 0.85 | HDAC11 (1.00) | HDAC11HDAC6HDAC1 | |
| SCHEMBL20096922 | 0.83 | HDAC11 (0.83) | HDAC11HDAC6HDAC1RIPK1 | |
| SCHEMBL20096849 | 0.82 | HDAC11 (0.78) | HDAC11HDAC6HDAC1RIPK1 | |
| SCHEMBL20096914 | 0.82 | HDAC11 (0.75) | HDAC11HDAC6HDAC1RIPK1 | |
| SCHEMBL20096552 | 0.81 | HDAC11 (0.73) | HDAC11HDAC6P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2019-03-21 | — | — | US | disclosed |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | VALO HEALTH, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-9246109-B2 | Compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885DRD2 4805/4885 |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885DRD2 4805/4885 |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885DRD2 4805/4885 |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885DRD2 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.